Trial Profile
A phase I dose escalation study of cisplatin, pemetrexed and radiotherapy for inoperable stage III non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Jan 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 05 Nov 2009 Additional trial identifiers (NTR752, 2208) identified as reported by Netherlands Trial Register.
- 25 Apr 2007 New trial record.